ClinicalTrials.gg
RecruitingNCT07791849Updated Nov 17, 2026

GMPA Versus PPI for Gastric Protection and aGVHD Risk

An interventional study of Teprenone and Esomeprazole in Hematopoietic Stem Cell Transplantation (HSCT), aGVHD and Infection, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by First Affiliated Hospital of Zhejiang University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 17, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Study summary

The goal of this clinical trial is to observe whether different gastric protection strategies affect the incidence of acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Proton pump inhibitors (PPIs) are routinely used for gastric protection during transplantation, but their prolonged use may suppress gastric acid, alter gut microbiota, and potentially increase the risk of aGVHD. Teprenone, a gastric mucosal protective agent (GMPA), enhances mucosal defense mechanisms including promoting mucus secretion, increasing gastric mucosal blood flow, and facilitating epithelial cell repair, without affecting gastric acid secretion, and may therefore preserve microbial diversity and modify aGVHD risk. This study compares two strategies: continuous PPI use versus switching from PPIs to teprenone after transplantation.

The main questions this study aims to answer are:

  • Does switching from PPIs to teprenone after transplantation reduce the cumulative incidence of aGVHD within +100 days post-transplantation compared with continuous PPI use?
  • What adverse events do participants experience with teprenone versus continuous PPI therapy?
  • Does teprenone therapy provide better preservation of gut microbial diversity and lower rates of gastrointestinal and infectious complications compared with continuous PPI use?

In this prospective, randomized, parallel-controlled, single-center trial, approximately 198 patients undergoing allo-HSCT will be enrolled and assigned in a 1:1 ratio using a central randomization system. The experimental group (teprenone group) will receive standard-dose PPIs (esomeprazole, 40 mg/d, intravenous/oral) during conditioning and switch to teprenone (50 mg tid, orally) after transplantation through day +100. The control group (PPI group) will receive continuous standard-dose PPIs from conditioning through day +100. Probiotic use is prohibited from conditioning through day +100 in both groups. All other anti-infective, GVHD prophylaxis, and supportive care regimens are identical between the two groups.

The primary endpoint of this study is the cumulative incidence of aGVHD within +100 days post-transplantation. Secondary endpoints include grade II-IV and grade III-IV aGVHD, lower gastrointestinal aGVHD, steroid-refractory aGVHD, gut and salivary microbiome dynamics (α-diversity, β-diversity, and specific taxa at pre-conditioning, day 0, day +14, and day +28), plasma biomarkers related to intestinal barrier integrity, systemic inflammation, and immune regulation , infectious and gastrointestinal complications (febrile neutropenia, diarrhea, C. difficile infection, bacteremia, EBV/CMV reactivation, upper GI bleeding, reflux), and 1-year survival outcomes (non-relapse mortality, overall survival, GVHD-free/relapse-free survival).

During the study, participants will:

  • Receive the assigned gastric protection regimen (teprenone or PPI) according to randomization
  • Undergo regular assessments for safety and efficacy monitoring, including aGVHD surveillance and infection screening
  • Provide fecal and saliva samples at pre-conditioning, day 0, day +14, and day +28 post-transplantation for microbiome analysis
  • Provide peripheral blood samples at pre-conditioning, day 0, day +14, and day +28 post-transplantation for exploratory analysis
  • Be followed for up to 1 year post-transplantation
02

Conditions studied

  • Hematopoietic Stem Cell Transplantation (HSCT)
  • aGVHD
  • Infection
  • Mortality
  • Microbiome

Browse trials for

Keywords

  • hematopoietic stem cell transplantation
  • PPI
  • GMPA
  • acute graft versus host disease
  • microbiome
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 362 are open to participants now.

This study's planned enrollment of 198 is above the median of 113 across 1,305 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

First Affiliated Hospital of Zhejiang University is the lead sponsor of 264 studies on the registry; 145 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 12-70 years;
  2. First allogeneic haploidentical for hematological ;
  3. Treated with a standardized myeloablative conditioning and prophylaxis regimen;
  4. performance status ≤2 prior to transplant;
  5. Written obtained.

Exclusion criteria

Exclusion Criteria:

  1. Pre-existing conditions requiring continuous PPI therapy prior to transplant, including severe reflux esophagitis, Zollinger-Ellison syndrome, active peptic ulcer with bleeding, or long-term use of dual antiplatelet agents or oral anticoagulants;
  2. Known active, untreated Helicobacter pylori infection prior to transplant;
  3. Active infectious enteritis or Clostridioides difficile infection prior to transplant;
  4. Use of systemic broad-spectrum antibiotics within 7 days prior to transplant;
  5. Use of probiotics within 14 days prior to transplant;
  6. Planned total enteral nutrition or oral glutamine supplementation during the study period;
  7. Planned parenteral nutrition for ≥7 consecutive days;
  8. Inability to provide saliva or stool samples for collection;
  9. Pregnant or lactating women;
  10. History of significant neurological or psychiatric disorders (e.g., epilepsy, dementia) that may interfere with study participation;
  11. \<3 months or severe end-organ dysfunction;
  12. Any other condition that, in the investigator's judgment, may compromise patient safety, compliance, or the validity of study results.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    GMPA group

    Participants in this arm will receive standard-dose proton pump inhibitor (PPI) during the conditioning phase. After transplantation, they will switch to teprenone, a gastric mucosal protective agent, at a dose of 50 mg three times daily (tid), administered orally, from the day of stem cell infusion through day +100 post-transplantation.

    Drug: Teprenone

  • Placebo comparator
    PPI Group

    Participants in this arm will receive continuous standard-dose proton pump inhibitor (PPI) therapy with esomeprazole at 40 mg daily, administered either intravenously or orally, from the start of conditioning through day +100 post-transplantation.

    Drug: Esomeprazole

Interventions

  • Teprenone acts by enhancing gastric mucosal defense mechanisms, including promoting mucus secretion, increasing gastric mucosal blood flow, and facilitating epithelial cell repair, without affecting gastric acid secretion. The switch from PPI to teprenone is intended to maintain gastric protection while potentially preserving gut microbial diversity and reducing the risk of acute graft-versus-host disease (aGVHD).

  • DrugEsomeprazole

    Continuous PPI use suppresses gastric acid secretion throughout the peri-transplantation period, which may alter gut microbiota composition and potentially influence aGVHD risk.

06

What researchers measure

Primary outcomes

  1. Incidence of acute graft-versus-host disease (aGVHD) post-transplantation

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first

Secondary outcomes

  1. Incidence of grade II-IV acute graft-versus-host disease (aGVHD)

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first

  2. Incidence of grade III-IV acute graft-versus-host disease (aGVHD)

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first

  3. Incidence of lower gastrointestinal aGVHD

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first

  4. Oral microbiome diversity and composition

    Time frame: At pre-conditioning, Day +0, Day +14, and Day +28 post-transplantation

  5. Fecal microbiome diversity and composition

    Time frame: At pre-conditioning, Day +0, Day +14, and Day +28 post-transplantation

  6. Incidence of febrile neutropenia

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first

  7. Incidence of diarrhea

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first

  8. Incidence of Clostridioides difficile infection

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up

  9. Incidence of enterococcal colonization/infection

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first

  10. Incidence of bacteremia

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first

  11. Incidence of upper gastrointestinal bleeding

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first

  12. Incidence of clinically significant reflux symptoms

    Time frame: From Day 0 to Day +100 post-transplantation, or until death or loss to follow-up, whichever came first

  13. 1-year non-relapse mortality (NRM)

    Time frame: From Day 0 to 1 year post-transplantation

  14. 1-year overall survival (OS)

    Time frame: From Day 0 to 1 year post-transplantation

  15. 1-year GVHD-free, relapse-free survival (GRFS)

    Time frame: From Day 0 to 1 year post-transplantation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zhu J, Sun C, Li M, Hu G, Zhao XM, Chen WH. Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial. Gut. 2024 Jun 6;73(7):1087-1097. doi: 10.1136/gutjnl-2023-330168. PubMed 38050061 ↗
  • Xiao X, Zhang X, Wang J, Liu Y, Yan H, Xing X, Yang J. Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study. Gut. 2024 Jun 6;73(7):1098-1109. doi: 10.1136/gutjnl-2023-330883. PubMed 38267200 ↗
  • Lee I, Jo JW, Woo HJ, Suk KT, Lee SS, Kim BS. Proton pump inhibitors increase the risk of carbapenem-resistant Enterobacteriaceae colonization by facilitating the transfer of antibiotic resistance genes among bacteria in the gut microbiome. Gut Microbes. 2024 Jan-Dec;16(1):2341635. doi: 10.1080/19490976.2024.2341635. Epub 2024 Apr 18. PubMed 38634770 ↗
  • Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020 Aug;69(8):1510-1519. doi: 10.1136/gutjnl-2019-320204. Epub 2020 May 14. PubMed 32409589 ↗
  • Imhann F, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY, Fu J, Wijmenga C, Zhernakova A, Weersma RK. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. Gut Microbes. 2017 Jul 4;8(4):351-358. doi: 10.1080/19490976.2017.1284732. Epub 2017 Jan 24. PubMed 28118083 ↗
  • Zhang X, Li Q, Xia S, He Y, Liu Y, Yang J, Xiao X. Proton Pump Inhibitors and Oral-Gut Microbiota: From Mechanism to Clinical Significance. Biomedicines. 2024 Oct 7;12(10):2271. doi: 10.3390/biomedicines12102271. PubMed 39457584 ↗
  • Nguyen CL, Funes J, Ghale R, Duong N, Victor K, Gipson B, Zhang ZJ, Dai A, Li R, Armijo G, Huang A, Martinez M, Chen Y, Ghazarian D, Docampo M, Pathak K, Pirrotte P, Markey KA, Peled JU, Paredes J, Burgos da Silva M, van den Brink MRM. Enterococcus faecalis induces MHC-II expression by the intestinal epithelium during murine graft-versus-host disease. Blood. 2026 Mar 26;147(13):1485-1497. doi: 10.1182/blood.2024028248. PubMed 41460962 ↗
  • Fujimoto K, Hayashi T, Yamamoto M, Sato N, Shimohigoshi M, Miyaoka D, Yokota C, Watanabe M, Hisaki Y, Kamei Y, Yokoyama Y, Yabuno T, Hirose A, Nakamae M, Nakamae H, Uematsu M, Sato S, Yamaguchi K, Furukawa Y, Akeda Y, Hino M, Imoto S, Uematsu S. An enterococcal phage-derived enzyme suppresses graft-versus-host disease. Nature. 2024 Aug;632(8023):174-181. doi: 10.1038/s41586-024-07667-8. Epub 2024 Jul 10. PubMed 38987594 ↗
  • Stein-Thoeringer CK, Nichols KB, Lazrak A, Docampo MD, Slingerland AE, Slingerland JB, Clurman AG, Armijo G, Gomes ALC, Shono Y, Staffas A, Burgos da Silva M, Devlin SM, Markey KA, Bajic D, Pinedo R, Tsakmaklis A, Littmann ER, Pastore A, Taur Y, Monette S, Arcila ME, Pickard AJ, Maloy M, Wright RJ, Amoretti LA, Fontana E, Pham D, Jamal MA, Weber D, Sung AD, Hashimoto D, Scheid C, Xavier JB, Messina JA, Romero K, Lew M, Bush A, Bohannon L, Hayasaka K, Hasegawa Y, Vehreschild MJGT, Cross JR, Ponce DM, Perales MA, Giralt SA, Jenq RR, Teshima T, Holler E, Chao NJ, Pamer EG, Peled JU, van den Brink MRM. Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science. 2019 Nov 29;366(6469):1143-1149. doi: 10.1126/science.aax3760. PubMed 31780560 ↗
  • Hayase E, Hayase T, Jamal MA, Miyama T, Chang CC, Ortega MR, Ahmed SS, Karmouch JL, Sanchez CA, Brown AN, El-Himri RK, Flores II, McDaniel LK, Pham D, Halsey T, Frenk AC, Chapa VA, Heckel BE, Jin Y, Tsai WB, Prasad R, Tan L, Veillon L, Ajami NJ, Wargo JA, Galloway-Pena J, Shelburne S, Chemaly RF, Davey L, Glowacki RWP, Liu C, Rondon G, Alousi AM, Molldrem JJ, Champlin RE, Shpall EJ, Valdivia RH, Martens EC, Lorenzi PL, Jenq RR. Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease. Cell. 2022 Sep 29;185(20):3705-3719.e14. doi: 10.1016/j.cell.2022.09.007. PubMed 36179667 ↗
  • Gao F, Wu H, Wang L, Zhao Y, Huang H. Altered intestinal microbiome and epithelial damage aggravate intestinal graft-versus-host disease. Gut Microbes. 2023 Jan-Dec;15(1):2221821. doi: 10.1080/19490976.2023.2221821. PubMed 37305973 ↗
  • van Lier YF, Vos J, Blom B, Hazenberg MD. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease. Gut Microbes. 2023 Jan-Dec;15(1):2178805. doi: 10.1080/19490976.2023.2178805. PubMed 36794370 ↗
  • Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, Giebel S, Greinix H, Hazenberg MD, Kroger N, Mielke S, Mohty M, Nagler A, Passweg J, Patriarca F, Ruutu T, Schoemans H, Solano C, Vrhovac R, Wolff D, Zeiser R, Sureda A, Peric Z. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024 Feb;11(2):e147-e159. doi: 10.1016/S2352-3026(23)00342-3. Epub 2024 Jan 3. PubMed 38184001 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

Of 276 non-industry interventional studies with no phase under Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 51. This study's planned 24 months is close to that.

Counting every sponsor, half of 307 studies reached it within 24 months; a quarter within 9 and three quarters within 50.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2026
First posted
Aug 28, 2026
StartActual
Sep 15, 2026
Primary completionEst.
Sep 15, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • The First Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, China
Show 1 removed
  • The First Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, China
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    1 site added, 1 site removed
    Show site
    • The First Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, China
    Show 1 removed
    • The First Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, China
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07791849
Responsible party
Yanmin Zhao (Vice Director, Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Zhejiang University) — Principal investigator
First posted
Aug 28, 2026
Start date
Sep 15, 2026
Primary completion
Sep 15, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Fei Gao
Contact
gf0906@zju.edu.cn
+86 19857035073

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Geranylgeranylacetone

Start the discussion